Simplify Logo

Full-Time

Principal Scientist

Cell-Free Protein Synthesis & Synthetic Biology

Confirmed live in the last 24 hours

Generate Biomedicines

Generate Biomedicines

51-200 employees

Generates novel medicines using machine learning

AI & Machine Learning
Biotechnology

Senior

Cambridge, MA, USA

Category
Computational Biology
Genomics
Biology Lab & Research
Biology & Biotech
Required Skills
Data Analysis
Requirements
  • PhD or equivalent and a minimum of 8+ years of experience in a relevant life sciences field (biophysics, biochemistry, biological engineering, quantitative/synthetic biology, or related discipline); or Master’s degree in a scientific field of study and 14 years of related experience; or Bachelor’s degree in a scientific field of study and 16 years of related experience
  • Demonstrated expertise in protein biochemistry including protein expression, purification, and assessment of protein biophysical properties
  • Deep subject matter expertise and experience with implementation and optimization of cell-free protein synthesis
  • Up-to-date knowledge and understanding of CFPS-relevant literature
  • Demonstrated experience in high-throughput experimental design and laboratory automation
Responsibilities
  • Expand Generate’s efforts to integrate CFPS into our HTP screening and production workflows
  • Lead part of the team efforts to optimize CFPS workflows using both experimental tools (strain engineering, protein biochemistry, synthetic biology) and theory (computational analysis, statistics, and ML-guided optimization)
  • Work together with members of the IDGS team to implement CFPS-based screening workflows involving micro-automation, microfluidics, and microfabricated devices
  • Work with production and analytics teams in the Protein Sciences department to optimize scaled-up workflows and implement characterization of CFPS-produced material
  • Generate bold, creative, unconventional ideas, and be a point person for intellectual property and patent writing
  • Strategic experiment planning, data interpretation, summarization, and presentation with minimal supervision are required
  • Involvement in accelerating the discovery, engineering and characterization of novel biologics in pipeline programs
  • Mentor and train scientists throughout the company
Generate Biomedicines

Generate Biomedicines

View

Generate Biomedicines focuses on creating new medicines using a method called generative biology, which combines machine learning and biological engineering. This approach involves analyzing millions of proteins to learn how nature encodes their functions, allowing the company to design new medicines with specific therapeutic effects. The main product, The Generate Platform, enables the rapid production of medicines across various therapeutic areas, significantly improving the drug discovery process compared to traditional methods. Unlike its competitors, Generate Biomedicines emphasizes a proactive and efficient approach to medicine creation, aiming to democratize access to biotherapeutics. The company's goal is to expand its capabilities in generating and testing proteins, having already produced 42,000 proteins, and to continue advancing the field of therapeutics.

Company Stage

Series C

Total Funding

$693M

Headquarters

Somerville, Massachusetts

Founded

2018

Growth & Insights
Headcount

6 month growth

2%

1 year growth

15%

2 year growth

41%
Simplify Jobs

Simplify's Take

What believers are saying

  • The recent $273M Series C financing round provides substantial capital to advance their generative AI pipeline and clinical programs.
  • Expansion of the leadership team with experienced professionals like Rupert Vessey, Nancy Simonian, and Kym White strengthens the company's strategic direction and operational capabilities.
  • Publication of the Chroma model in Nature highlights the company's innovative contributions to protein therapeutics, enhancing its reputation in the scientific community.

What critics are saying

  • The reliance on cutting-edge generative AI and machine learning technologies may face regulatory and adoption challenges in the conservative pharmaceutical industry.
  • Rapid expansion and scaling efforts, including new hires and leadership changes, could lead to integration and cultural challenges.

What makes Generate Biomedicines unique

  • Generate Biomedicines leverages generative biology and machine learning to create medicines on demand, a significant departure from traditional drug discovery methods.
  • The Generate Platform's ability to produce novel medicines across multiple therapeutic areas with high speed and success rates sets it apart from competitors.
  • Their focus on understanding the rules by which nature encodes function to design new proteins is a unique approach in the biotechnology sector.